Related Experiment Video
Updated: May 26, 2026
12:55
Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells
Published on: October 10, 2017
Curcumin: a potential neuroprotective agent in Parkinson's disease
R B Mythri1, M M Srinivas Bharath
1Department of Neurochemistry, National Institute of Mental Health and Neurosciences, Bangalore-560029, Karnataka, India.
Current Pharmaceutical Design
|January 4, 2012
Summary
Curcumin, a natural compound from turmeric, shows promise as a neuroprotective agent for Parkinson's disease (PD). This review explores its potential to combat neurodegeneration and improve PD symptoms beyond current dopamine-replenishing therapies.
Area of Science:
- Neuroscience
- Pharmacology
- Natural Product Chemistry
Background:
- Parkinson's disease (PD) is a neurodegenerative disorder causing motor deficits due to dopamine neuron loss.
- Current PD treatments replenish dopamine but cause complications and don't halt progression.
- There is a need for neuroprotective therapies, including natural antioxidants like curcumin.
Purpose of the Study:
- To review the therapeutic potential of curcumin in Parkinson's disease.
- To explore curcumin's neuroprotective properties and efficacy in experimental PD models.
Main Methods:
- Literature review of studies on curcumin and Parkinson's disease.
- Analysis of curcumin's antioxidant, anti-inflammatory, and neuroprotective mechanisms.
- Evaluation of preclinical evidence for curcumin's efficacy in PD models.
Main Results:
- Curcumin exhibits antioxidant, anti-inflammatory, and neuroprotective effects.
- Curcumin can cross the blood-brain barrier, reaching the central nervous system.
- Preclinical studies suggest curcumin's potential benefits in various experimental models of PD.
Conclusions:
- Curcumin demonstrates significant therapeutic potential for Parkinson's disease.
- Its neuroprotective properties make it a promising candidate for adjunctive therapy in PD.
- Further clinical research is warranted to confirm curcumin's efficacy and safety in PD patients.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...